Global Study of Del-desiran for the Treatment of DM1
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1